SLC5A2 and chronic kidney disease: The effectiveness of SGLT-2 inhibitors in reducing kidney outcomes appears to be consistent regardless of baseline kidney function, with an overall hazard ratio of 0.66 (95% CI, 0.61 to 0.71) Across diverse CKD populations, SGLT-2 inhibitors demonstrated a consistent reduction in the risk of kidney events (HR 0.64, 95% CI, 0.59 to 0.70) (25).